RxDoctor Payments DataLook up a doctor →

Glenn Gandelman, MD

Cardiovascular Disease · Greenwich, CTNPI 1033117437

Payments from drug & device makers

$165,022in general payments, 2019–2025

Across 510 payments — averaging $323.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$155K
  • AstraZeneca$1K
  • AbbVie$1K
  • Exact Sciences$703
  • Novo Nordisk$654
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$644
  • plus $6K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis66$154,875
AstraZeneca20$1,408
AbbVie(2 entities)44$1,110
Exact Sciences30$703
Novo Nordisk30$654
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC36$644
Boehringer Ingelheim27$543
Johnson & Johnson24$410
Idorsia Pharmaceuticals US Inc22$347
Amarin Pharma, Inc.17$314
E.r. Squibb & Sons, L.L.C.15$293
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)12$284
Sumitomo Pharma America, Inc.11$260
GSK11$256
Merck13$248
Amgen12$236
Kowa Pharmaceuticals America, Inc.17$234
Pfizer11$198
Abbott7$162
Esperion Therapeutics, Inc.7$155
QOL Medical, LLC5$139
Lilly USA, LLC7$128
Bayer6$122
Bausch Health US, LLC5$115
Sanofi-aventis U.S. LLC6$114
Corium, LLC4$85
Takeda Pharmaceuticals U.S.A., Inc.3$70
Antares Pharma, Inc.3$68
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$64
Upsher-smith Laboratories LLC3$61
Lexicon Pharmaceuticals, Inc.2$57
Medtronic1$54
Nestle Healthcare Nutrition Inc.3$53
Boston Scientific1$49
Alnylam Pharmaceuticals Inc.2$43
Otsuka America Pharmaceutical, Inc.2$41
Actelion Pharmaceuticals US, Inc.1$37
Baxter Healthcare1$30
Biohaven Pharmaceutical Holding Company Ltd.2$29
Gilead2$27
Lundbeck LLC1$27
Impel Pharmaceuticals Inc.1$25
Cleerly, Inc.1$24
Almatica Pharma LLC1$23
Ironwood Pharmaceuticals, Inc1$22
Jazz Pharmaceuticals Inc.1$21
Itamar Medical Inc1$21
Dexcom, Inc.1$20
Optinose US, Inc.1$19
Vivaquant Inc, Dba Rhythm Express1$19
Azurity Pharmaceuticals, Inc.1$18
Phathom Pharmaceuticals, Inc.1$17
Endo Pharmaceuticals Inc.1$15
Phadia US Inc.1$14
Regeneron Healthcare Solutions, Inc.1$12
Bardy Diagnostics, Inc.1$7

How this compares

$165,022 in reported general payments places this provider in the 90th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$1,106,195
Medicare patients
2,854
Services billed
11,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Greenwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →